AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Oil Prices Surge Amid U.S.-Iran Tensions and Supply Disruption Fears 
US Stock Futures Rise as S&P 500 and Nasdaq Hit Record Highs Amid Earnings Optimism and Iran Tensions 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Asian Stock Markets Rise Amid Wall Street Rally and U.S.-Iran Tensions 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Stock Market Update: Fed Holds Rates Steady as Tech Earnings and Geopolitical Tensions Shape Outlook 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Trump Rejects Iran Proposal as Tensions Persist Amid Fragile Ceasefire 
Oil Prices Fall as Iran Proposes New Deal Amid Ongoing U.S. Tensions 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
US Stock Futures Mixed as Fed Holds Rates, Oil Prices Surge, and Big Tech Earnings Drive Market Moves 
Samsung Biologics just opened the largest Contract Development and Manufacturing Organization (CDMO) plant in the world, and it is located in Incheon, South Korea. The biotech firm is now hoping that through its new pharmaceutical facility, it will be able to replicate the success of its chip manufacturing business.
Samsung Biologics inaugurated the plant on Tuesday, Oct. 11, and it was attended by the vice chairman of Samsung Electronics, Lee Jae Yong. The facility is now the biopharma firm’s fourth factory.
The company usually has an annual production capacity of 240,000 liters and this will now become 420,000 liters as the new plant starts its partial operation. The construction of the Songdo plant began in 2020, and it is expected to go into full operation next year.
As per Korea Joongang Daily, once it runs in full force, Samsung Biologics is expecting to further increase its production capacity up to 620,000 liters. The company said this amount is equivalent to almost 30% of the global contract manufacturing capacity for biopharma firms.
With this volume, Samsung Biologics defeated Switzerland’s Lonza Group AG and Germany's Boehringer Ingelheim pharmaceutical and biotech companies.
In any case, Samsung invested KRW2 trillion or about $1.4 billion for the construction of its new Songdo plant, and in the future, the company may spend a total of KRW7 trillion on building its fifth, sixth, seventh, and eighth plants in the same region but on another site. Samsung Biologics is expanding its facilities to accommodate more orders from its major global clients, such as Pfizer, GlaxoSmithKline, Moderna, Eli Lilly, and AstraZeneca.
Meanwhile, the Samsung chief met with the senior executives of Samsung Biologics and Samsung Bioepis after the inauguration ceremony for the Songdo factory. They talked about mid and long-term strategies to improve competitiveness as CDMO and a biosimilar manufacturer.
The Korea Times reported that at the meeting, Lee Jae Yong vowed to put in a new investment of KRW7.5 trillion or $5.2 billion to widen the gap from its rivals in the bio business and move ahead to become the leader in the industry. He said that Samsung will release the fund for its biotech unit by 2032.
